(CORT) Corcept Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.465m USD | Total Return: -11.9% in 12m
Avg Turnover: 63.1M
EPS Trend: -34.7%
Qual. Beats: -1
Rev. Trend: 97.6%
Qual. Beats: -3
Warnings
P/E ratio 172.1
High Debt/EBITDA (53.0) with thin interest coverage (-0.3)
Interest Coverage Ratio -0.3 is critical
Extended 1w
Tailwinds
Supp Ema8, Idiosyncratic Leader
Corcept Therapeutics Incorporated is a California-based biopharmaceutical company specializing in the development of selective cortisol modulators to treat severe endocrine, oncologic, and metabolic disorders. The companys primary commercial product, Korlym, targets hyperglycemia in patients with endogenous Cushings syndrome who are ineligible for surgery. As a pharmaceutical firm focused on cortisol regulation, Corcept operates within a high-barrier-to-entry sector characterized by intensive research and development cycles and stringent regulatory oversight.
The companys clinical pipeline includes relacorilant for hypercortisolism and miricorilant for metabolic dysfunction-associated steatohepatitis (MASH). Corcept is also investigating cortisol modulators for neurological applications, specifically Lou Gehrigs disease. Biopharmaceutical business models often rely on patent protections to maintain market exclusivity for specialized orphan drugs that address unmet medical needs. Investors can find additional fundamental analysis on ValueRay to deepen their understanding of the companys market position.
- Korlym sales growth drives primary revenue and funds ongoing clinical pipeline development
- Relacorilant phase 3 data results determine future market exclusivity and growth potential
- Generic competition litigation outcomes threaten long-term Korlym revenue and profit margins
- Pipeline expansion into oncology and metabolic disorders diversifies future earnings potential
- Regulatory approval timelines for new cortisol modulators dictate mid-term stock valuation shifts
| Net Income: 47.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -6.23 > 1.0 |
| NWC/Revenue: 36.00% < 20% (prev 43.10%; Δ -7.10% < -1%) |
| CFO/TA 0.15 > 3% & CFO 120.1m > Net Income 47.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.4m) vs 12m ago -12.84% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 92.59% > 50% (prev 80.98%; Δ 11.61% > 0%) |
| Interest Coverage Ratio: -0.28 > 6 (EBITDA TTM -6.19m / Interest Expense TTM 29.3m) |
| A: 0.34 (Total Current Assets 426.0m - Total Current Liabilities 149.2m) / Total Assets 814.9m |
| B: 0.75 (Retained Earnings 611.6m / Total Assets 814.9m) |
| C: -0.01 (EBIT TTM -8.22m / Avg Total Assets 830.7m) |
| D: 3.46 (Book Value of Equity 612.7m / Total Liabilities 176.9m) |
| Altman-Z'' = 8.25 = AAA |
| DSRI: 0.41 (Receivables 39.1m/84.4m, Revenue 769.1m/685.4m) |
| GMI: 1.00 (GM 98.25% / 98.43%) |
| AQI: 0.98 (AQ_t 0.46 / AQ_t-1 0.47) |
| SGI: 1.12 (Revenue 769.1m / 685.4m) |
| TATA: -0.09 (NI 47.9m - CFO 120.1m) / TA 814.9m) |
| Beneish M = -3.52 (Cap -4..+1) = AAA |
As of May 29, 2026, the stock is trading at USD 68.38 with a total of 1,084,771 shares traded.
Over the past week, the price has changed by +15.78%,
over one month by +46.68%,
over three months by +91.54% and
over the past year by -11.94%.
Corcept Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CORT.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 79 | 15.5% |
P/E Trailing = 172.0571
P/E Forward = 75.188
P/S = 8.4056
P/B = 10.0438
P/EG = 0.813
Revenue TTM = 769.1m USD
EBIT TTM = -8.22m USD
EBITDA TTM = -6.19m USD
Long Term Debt = 8.01m USD (estimated: total debt 9.64m - short term 1.63m)
Short Term Debt = 1.63m USD (from shortTermDebt, last quarter)
Debt = 9.64m USD (from shortLongTermDebtTotal, last quarter) (leases 9.64m already included)
Net Debt = -328.5m USD (calculated: Debt 9.64m - CCE 338.2m)
Enterprise Value = 6.14b USD (6.46b + Debt 9.64m - CCE 338.2m)
Interest Coverage Ratio = -0.28 (Ebit TTM -8.22m / Interest Expense TTM 29.3m)
EV/FCF = 51.23x (Enterprise Value 6.14b / FCF TTM 119.8m)
FCF Yield = 1.95% (FCF TTM 119.8m / Enterprise Value 6.14b)
FCF Margin = 15.58% (FCF TTM 119.8m / Revenue TTM 769.1m)
Net Margin = 6.23% (Net Income TTM 47.9m / Revenue TTM 769.1m)
Gross Margin = unknown ((Revenue TTM 769.1m - Cost of Revenue TTM 13.5m) / Revenue TTM)
Tobins Q-Ratio = 7.53 (Enterprise Value 6.14b / Total Assets 814.9m)
Interest Expense / Debt = 303.5% (Interest Expense 29.3m / Debt 9.64m)
Taxrate = 21.0% (US default 21%)
NOPAT = -6.49m (EBIT -8.22m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 426.0m / Total Current Liabilities 149.2m)
Debt / Equity = 0.02 (Debt 9.64m / totalStockholderEquity, last quarter 638.0m)
Debt / EBITDA = 53.04 (negative EBITDA) (Net Debt -328.5m / EBITDA -6.19m)
Debt / FCF = -2.74 (Net Debt -328.5m / FCF TTM 119.8m)
Total Stockholder Equity = 638.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.77% (Net Income 47.9m / Total Assets 814.9m)
RoE = 7.50% (Net Income TTM 47.9m / Total Stockholder Equity 638.4m)
RoCE = -1.27% (EBIT -8.22m / Capital Employed (Equity 638.4m + L.T.Debt 8.01m))
RoIC = -0.97% (negative operating profit) (NOPAT -6.49m / Invested Capital 667.3m)
WACC = 11.57% (E(6.46b)/V(6.47b) * Re(11.59%) + (debt cost/tax rate unavailable))
Discount Rate = 11.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 42.22 | Cagr: -2.63%
[DCF] Terminal Value 62.09% ; FCFF base≈142.7m ; Y1≈125.2m ; Y5≈101.1m
[DCF] Fair Price = 12.97 (EV 1.06b - Net Debt -328.5m = Equity 1.39b / Shares 107.4m; r=11.57% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -34.68 | EPS CAGR: -12.49% | SUE: -1.74 | # QB: -1
Revenue Correlation: 97.62 | Revenue CAGR: 25.74% | SUE: -1.07 | # QB: -3
EPS current Quarter (2026-06-30): EPS=0.04 | Chg30d=-29.42% | Revisions=-14% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.25 | Chg30d=+54.32% | Revisions=+14% | Analysts=3
EPS current Year (2026-12-31): EPS=0.48 | Chg30d=+17.61% | Revisions=+14% | GrowthEPS=-41.8% | GrowthRev=+29.8%
EPS next Year (2027-12-31): EPS=1.63 | Chg30d=+1.37% | Revisions=+14% | GrowthEPS=+241.4% | GrowthRev=+30.5%
[Analyst] Revisions Ratio: -14%